Why the study?
Does pioglitazone improve endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors?
Does pioglitazone improve endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors?
In nondiabetic patients with cardiovascular risk factors, pioglitazone improves endothelial vasodilator function and insulin sensitivity, suggesting beneficial vascular properties independent of its metabolic effects.
No takes yet. Share an insight, caveat, or question.
Pioglitazone may confer endothelial benefit in nondiabetic patients with CV risk factors; extends evidence for vascular effects independent of glycemia.
Campia et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: